1
|
Thomas S, Fiebig JE, Kuhn EM, Mayer DS, Filbeck S, Schmitz W, Krischke M, Gropp R, Mueller TD. Design of Glycoengineered IL-4 Antagonists Employing Chemical and Biosynthetic Glycosylation. ACS OMEGA 2023; 8:24841-24852. [PMID: 37483220 PMCID: PMC10357448 DOI: 10.1021/acsomega.3c00726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 06/13/2023] [Indexed: 07/25/2023]
Abstract
Interleukin-4 (IL-4) plays a key role in atopic diseases. It coordinates T-helper cell differentiation to subtype 2, thereby directing defense toward humoral immunity. Together with Interleukin-13, IL-4 further induces immunoglobulin class switch to IgE. Antibodies of this type activate mast cells and basophilic and eosinophilic granulocytes, which release pro-inflammatory mediators accounting for the typical symptoms of atopic diseases. IL-4 and IL-13 are thus major targets for pharmaceutical intervention strategies to treat atopic diseases. Besides neutralizing antibodies against IL-4, IL-13, or its receptors, IL-4 antagonists can present valuable alternatives. Pitrakinra, an Escherichia coli-derived IL-4 antagonist, has been evaluated in clinical trials for asthma treatment in the past; however, deficits such as short serum lifetime and potential immunogenicity among others stopped further development. To overcome such deficits, PEGylation of therapeutically important proteins has been used to increase the lifetime and proteolytic stability. As an alternative, glycoengineering is an emerging strategy used to improve pharmacokinetics of protein therapeutics. In this study, we have established different strategies to attach glycan moieties to defined positions in IL-4. Different chemical attachment strategies employing thiol chemistry were used to attach a glucose molecule at amino acid position 121, thereby converting IL-4 into a highly effective antagonist. To enhance the proteolytic stability of this IL-4 antagonist, additional glycan structures were introduced by glycoengineering utilizing eucaryotic expression. IL-4 antagonists with a combination of chemical and biosynthetic glycoengineering could be useful as therapeutic alternatives to IL-4 neutralizing antibodies already used to treat atopic diseases.
Collapse
Affiliation(s)
- Sarah Thomas
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Juliane E. Fiebig
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Eva-Maria Kuhn
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Dominik S. Mayer
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Sebastian Filbeck
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Werner Schmitz
- Department
of Biochemistry and Molecular Biology, Biocenter
of the University Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
| | - Markus Krischke
- Department
of Pharmaceutical Biology, Julius-von-Sachs
Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| | - Roswitha Gropp
- Department
of General- Visceral-, Vascular- and Transplantation Surgery, Hospital of the LMU, Nussbaumstr. 20, 80336 Munich, Germany
| | - Thomas D. Mueller
- Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany
| |
Collapse
|
2
|
Gevenois PJLY, De Pauw P, Schoonooghe S, Delporte C, Sebti T, Amighi K, Muyldermans S, Wauthoz N. Development of Neutralizing Multimeric Nanobody Constructs Directed against IL-13: From Immunization to Lead Optimization. THE JOURNAL OF IMMUNOLOGY 2021; 207:2608-2620. [PMID: 34645688 DOI: 10.4049/jimmunol.2100250] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 09/16/2021] [Indexed: 11/19/2022]
Abstract
IL-13 is a pleiotropic cytokine mainly secreted by Th2 cells. It reacts with many different types of cells involved in allergy, inflammation, and fibrosis, e.g., mastocytes, B cells, and fibroblasts. The role of IL-13 in conditions involving one or several of these phenotypes has therefore been extensively investigated. The inhibition of this cytokine in animal models for various pathologies yielded highly promising results. However, most human trials relying on anti-IL-13 conventional mAbs have failed to achieve a significant improvement of the envisaged disorders. Where some studies might have suffered from several weaknesses, the strategies themselves, such as targeting only IL-13 using conventional mAbs or employing a systemic administration, could be questioned. Nanobodies are recombinant Ag-binding fragments derived from the variable part of H chain-only Abs occurring in Camelidae. Thanks to their single-domain structure, small size (≈15 kDa), good stability, and solubility, they can be engineered into multispecific constructs for combined therapies or for use in new strategies such as formulations for local administration, e.g., pulmonary administration. In this study, we describe the generation of 38 nanobodies that can be subdivided into five CDR3 families. Nine nanobodies were found to have a good affinity profile (KD = 1-200 nM), but none were able to strongly inhibit IL-13 biological activity in vitro (IC50 > 50 µM: HEK-Blue IL-13/IL-4 cells). Multimeric constructs were therefore designed from these inhibitors and resulted in an up to 36-fold improvement in affinity and up to 300-fold enhancement of the biological activity while conserving a high specificity toward IL-13.
Collapse
Affiliation(s)
- Philippe J-L Y Gevenois
- Unit of Pharmaceutics and Biopharmaceutics, Free University of Brussels, Faculty of Pharmacy, Brussels, Belgium;
| | - Pieter De Pauw
- Laboratory of Cellular and Molecular Immunology, Free University of Brussels, Ixelles, Belgium
| | - Steve Schoonooghe
- Flemish Institute for Biotechnology Nanobody Core, Free University of Brussels, Brussels, Belgium
| | - Cédric Delporte
- Unit of Pharmacognosy, Bioanalysis and Drug Discovery, RD3 and Analytical Platform of the Faculty of Pharmacy, Free University of Brussels, Brussels, Belgium; and
| | | | - Karim Amighi
- Unit of Pharmaceutics and Biopharmaceutics, Free University of Brussels, Faculty of Pharmacy, Brussels, Belgium
| | - Serge Muyldermans
- Laboratory of Cellular and Molecular Immunology, Free University of Brussels, Ixelles, Belgium
| | - Nathalie Wauthoz
- Unit of Pharmaceutics and Biopharmaceutics, Free University of Brussels, Faculty of Pharmacy, Brussels, Belgium
| |
Collapse
|
3
|
Tully M, Hauptstein N, Licha K, Meinel L, Lühmann T, Haag R. Linear Polyglycerol for N-terminal-selective Modification of Interleukin-4. J Pharm Sci 2021; 111:1642-1651. [PMID: 34728175 DOI: 10.1016/j.xphs.2021.10.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 10/26/2021] [Accepted: 10/26/2021] [Indexed: 01/13/2023]
Abstract
Polymer conjugation to biologics is of key interest to the pharmaceutical industry for the development of potent and long acting biotherapeutics, with poly(ethylene glycol) (PEG) being the gold standard. Within the last years, unwanted PEG-related side effects (immunological reactions, antibody formation) arose, therefore creating several attempts to establish alternative polymers with similar potential to PEG. In this article, we synthesized N-terminal bioconjugates of the potential therapeutic human interleukin-4 (hIL-4 WT) with linear polyglycerol (LPG) of 10 and 40 kDa and compared it with its PEG analogs of same nominal weights. Polyglycerol is a highly hydrophilic polymer with good biocompatibility and therefore represents an alternative polymer to PEG. Both polymer types resulted in similar conjugation yields, comparable hydrodynamic sizes and an unaltered secondary structure of the protein after modification. LPG- and PEG-bioconjugates remained stable in human plasma, whereas binding to human serum albumin (HSA) decreased after polymer modification. Furthermore, only minor differences in bioactivity were observed between LPG- and PEG-bioconjugates of same nominal weights. The presented findings are promising for future pharmacokinetic evaluation of hIL-4-polymer bioconjugates.
Collapse
Affiliation(s)
- Michael Tully
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195 Berlin Germany
| | - Niklas Hauptstein
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg Germany
| | - Kai Licha
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195 Berlin Germany
| | - Lorenz Meinel
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg Germany; Helmholtz Institute for RNA-Based Infection Research (HIRI), Helmholtz Center for Infection Research (HZI), 97080 Würzburg, Germany
| | - Tessa Lühmann
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg Germany
| | - Rainer Haag
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195 Berlin Germany.
| |
Collapse
|
4
|
Naz S, Ashraf S, Parvez MK, Al-Dosari MS, Ul-Haq Z. Structure and ligand-based drug discovery of IL-4 inhibitors via interaction-energy-based learning approaches. J Biomol Struct Dyn 2021; 40:6503-6521. [PMID: 33618633 DOI: 10.1080/07391102.2021.1886172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Interleukin-4 (IL-4), an anti-inflammatory cytokine plays significant in the development of various diseases especially asthmatic allergies. Previous structural and functional studies of IL-4 with its receptor bring forth different types of inhibitors to block their interaction but each of them failed in clinical trials. Since, no synthetic molecules have been identified against IL-4, so far. Therefore, 21 in-house tested IL-4 inhibitors were blindly docked over the entire surface of IL-4 to predict a suitable and druggable binding site as the crystal structure of IL-4 protein in complex with ligand has not been reported yet. After binding site prediction, both ligand-based and structure-based pharmacophore were generated to screen three ZINC libraries (24.5 M) i.e. purchasable, natural product and natural derivative. A total 5,800 top-scored compounds were further subjected towards score-based screening to find the potential leads. Following protein-ligand interaction fingerprints (PLIF) and molecular visualization of selected hits, six top-scored compounds (five from purchasable and one from natural product library) were further moved towards their stability dynamics, followed by their absolute binding free energy and residue-based energy decomposition calculation by MM-GBSA method. These efforts help us to reveal the key factors responsible for ligand binding that might help to improve the binding and stability of these newly discovered hits by structural modifications.Communicated by Freddie R. Salsbury.
Collapse
Affiliation(s)
- Sehrish Naz
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
| | - Sajda Ashraf
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
| | - Mohammad K Parvez
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Mohammed S Al-Dosari
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Zaheer Ul-Haq
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
| |
Collapse
|
5
|
Kim JE, Jung K, Kim JA, Kim SH, Park HS, Kim YS. Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity. Sci Rep 2019; 9:7772. [PMID: 31123339 PMCID: PMC6533264 DOI: 10.1038/s41598-019-44253-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 05/13/2019] [Indexed: 01/10/2023] Open
Abstract
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (TH2)-mediated allergic diseases such as asthma and atopic dermatitis. Here we isolated anti-human IL-4Rα antagonistic Abs from a large yeast surface-displayed human Ab library and further engineered their complementarity-determining regions to improve the affinity using yeast display technology, finally generating a candidate Ab, 4R34.1.19. When reformatted as human IgG1 form, 4R34.1.19 specifically bound to IL-4Rα with a high affinity (KD ≈ 178 pM) and effectively blocked IL-4- and IL-13-dependent signaling in a reporter cell system at a comparable level to that of the clinically approved anti-IL-4Rα dupilumab Ab analogue. Epitope mapping by alanine scanning mutagenesis revealed that 4R34.1.19 mainly bound to IL-4 binding sites on IL-4Rα with different epitopes from those of dupilumab analogue. Further, 4R34.1.19 efficiently inhibited IL-4-dependent proliferation of T cells among human peripheral blood mononuclear cells and suppressed the differentiation of naïve CD4+ T cells from healthy donors and asthmatic patients into TH2 cells, the activities of which were comparable to those of dupilumab analogue. Our work demonstrates that both affinity and epitope are critical factors for the efficacy of anti-IL-4Rα antagonistic Abs.
Collapse
Affiliation(s)
- Jung-Eun Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| | - Keunok Jung
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea
| | - Jeong-Ah Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea
| | - Seung-Hyun Kim
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea
| | - Hae-Sim Park
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea
| | - Yong-Sung Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea.
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.
| |
Collapse
|
6
|
Lühmann T, Schmidt M, Leiske MN, Spieler V, Majdanski TC, Grube M, Hartlieb M, Nischang I, Schubert S, Schubert US, Meinel L. Site-Specific POxylation of Interleukin-4. ACS Biomater Sci Eng 2017; 3:304-312. [DOI: 10.1021/acsbiomaterials.6b00578] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Tessa Lühmann
- Institute
of Pharmacy and Food Chemistry, University of Würzburg, Am
Hubland, DE-97074 Würzburg, Germany
| | - Marcel Schmidt
- Institute
of Pharmacy and Food Chemistry, University of Würzburg, Am
Hubland, DE-97074 Würzburg, Germany
| | - Meike N. Leiske
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Valerie Spieler
- Institute
of Pharmacy and Food Chemistry, University of Würzburg, Am
Hubland, DE-97074 Würzburg, Germany
| | - Tobias C. Majdanski
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Mandy Grube
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Matthias Hartlieb
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Ivo Nischang
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Stephanie Schubert
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
- Department
of Pharmaceutical Technology, Friedrich Schiller University Jena, Otto-Schott-Strasse 41, DE-07747 Jena, Germany
| | - Ulrich S. Schubert
- Institute of Organic and Macromolecular Chemistry [IOMC], Friedrich Schiller University Jena, Humboldtstrasse 10, DE-07743 Jena, Germany
- Jena
Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, DE-07743 Jena, Germany
| | - Lorenz Meinel
- Institute
of Pharmacy and Food Chemistry, University of Würzburg, Am
Hubland, DE-97074 Würzburg, Germany
| |
Collapse
|
7
|
Lühmann T, Spieler V, Werner V, Ludwig MG, Fiebig J, Mueller TD, Meinel L. Interleukin-4-Clicked Surfaces Drive M2 Macrophage Polarization. Chembiochem 2016; 17:2123-2128. [DOI: 10.1002/cbic.201600480] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Indexed: 01/27/2023]
Affiliation(s)
- Tessa Lühmann
- Institute for Pharmacy and Food Chemistry; University of Würzburg; Am Hubland 97074 Würzburg Germany
| | - Valerie Spieler
- Institute for Pharmacy and Food Chemistry; University of Würzburg; Am Hubland 97074 Würzburg Germany
| | - Vera Werner
- Institute for Pharmacy and Food Chemistry; University of Würzburg; Am Hubland 97074 Würzburg Germany
| | | | - Juliane Fiebig
- Lehrstuhl für Botanik I Molekulare Pflanzenphysik und Biophysik; University of Würzburg; Julius-von-Sachs-Platz 2 97082 Würzburg Germany
| | - Thomas D. Mueller
- Lehrstuhl für Botanik I Molekulare Pflanzenphysik und Biophysik; University of Würzburg; Julius-von-Sachs-Platz 2 97082 Würzburg Germany
| | - Lorenz Meinel
- Institute for Pharmacy and Food Chemistry; University of Würzburg; Am Hubland 97074 Würzburg Germany
| |
Collapse
|
8
|
Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev 2016; 32:3-15. [PMID: 27165851 DOI: 10.1016/j.cytogfr.2016.04.002] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 03/23/2016] [Accepted: 04/15/2016] [Indexed: 01/23/2023]
Abstract
Studies on Interlukin-4 (IL-4) disclosed great deal of information about its various physiological and pathological roles. All these roles depend upon its interaction and signaling through either type-I (IL-4Rα/common γ-chain) or type-II (IL-4Rα/IL-13Rα) receptors. Another cytokine, IL-13, shares some of the functions of IL-4, because both cytokines use a common receptor subunit, IL-4Rα. Here in this review, we discuss the structural details of IL-4 and IL-4Rα subunit and the structural similarities between IL-4 and IL-13. We also describe detailed chemistry of type-I and type-II receptor complexes and their signaling pathways. Furthermore, we elaborate the strength of type-II hetero dimer signals in response to IL-4 and IL-13. These cytokines are prime players in pathogenesis of allergic asthma, allergic hypersensitivity, different cancers, and HIV infection. Recent advances in the structural and binding chemistry of these cytokines various types of inhibitors were designed to block the interaction of IL-4 and IL-13 with their receptor, including several IL-4 mutant analogs and IL-4 antagonistic antibodies. Moreover, different targeted immunotoxins, which is a fusion of cytokine protein with a toxin or suicidal gene, are the new class of inhibitors to prevent cancer progression. In addition few small molecular inhibitors such as flavonoids have also been developed which are capable of binding with high affinity to IL-4Rα and, therefore, can be very effective in blocking IL-4-mediated responses.
Collapse
|
9
|
Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clin Exp Metastasis 2015; 32:847-56. [PMID: 26385103 DOI: 10.1007/s10585-015-9747-9] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2015] [Accepted: 09/10/2015] [Indexed: 12/31/2022]
Abstract
While progress has been made in treating primary epithelial tumors, metastatic tumors remain largely incurable and still account for 85-90 % of all cancer-related deaths. Interleukin-4 (IL4), a Th2 cytokine, and the IL4/IL4 receptor (IL4R) interaction have well defined roles in the immune system. Yet, IL4 receptors are over-expressed by many epithelial cancers and could be a promising target for metastatic tumor therapy. The IL4/IL4R signaling axis is a strong promoter of pro-metastatic phenotypes in epithelial cancer cells including enhanced migration, invasion, survival, and proliferation. The promotion of breast cancer growth specifically is also supported in part by IL4-induced glutamine metabolism, and we have shown that IL4 is also capable of inducing glucose metabolism in breast cancer cells. Importantly, there are several types of FDA approved medications for use in asthma patients that inhibit the IL4/IL4R signaling axis. However, these approved medications inhibit both the type I IL4 receptor found on immune cells, and the type II IL4 receptor that is predominantly expressed by some non-hematopoietic cells including epithelial cancer cells. This article reviews existing therapies targeting IL4, IL4R, or IL4/IL4R signaling, and recent findings guiding the creation of novel therapies that specifically inhibit the type II IL4R, while taking into consideration effects on immune cells within the tumor microenvironment. Some of these therapies are currently in clinical trials for cancer patients, and may be exploitable for the treatment of metastatic disease.
Collapse
|
10
|
McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015; 75:38-50. [PMID: 26187331 PMCID: PMC4546937 DOI: 10.1016/j.cyto.2015.05.023] [Citation(s) in RCA: 216] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2015] [Revised: 05/16/2015] [Accepted: 05/21/2015] [Indexed: 12/21/2022]
Abstract
Interleukin (IL)-4 and IL-13 were discovered approximately 30years ago and were immediately linked to allergy and atopic diseases. Since then, new roles for IL-4 and IL-13 and their receptors in normal gestation, fetal development and neurological function and in the pathogenesis of cancer and fibrosis have been appreciated. Studying IL-4/-13 and their receptors has revealed important clues about cytokine biology and led to the development of numerous experimental therapeutics. Here we aim to highlight new discoveries and consolidate concepts in the field of IL-4 and IL-13 structure, receptor regulation, signaling and experimental therapeutics.
Collapse
Affiliation(s)
- Sarah M McCormick
- Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
| | - Nicola M Heller
- Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Division of Allergy and Clinical Immunology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
| |
Collapse
|
11
|
Kurgonaite K, Gandhi H, Kurth T, Pautot S, Schwille P, Weidemann T, Bökel C. Essential role of endocytosis for Interleukin-4 receptor mediated JAK/STAT signalling. J Cell Sci 2015; 128:3781-95. [DOI: 10.1242/jcs.170969] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Accepted: 08/21/2015] [Indexed: 01/15/2023] Open
Abstract
Many important signalling cascades operate through specialized signalling endosomes, but a corresponding mechanism has as yet not been described for hematopoietic cytokine receptors. Based on live cell affinity measurements we recently proposed that ligand induced Interleukin-4 receptor (IL-4R) complex formation and thus JAK/STAT pathway activation requires a local, subcellular increase in receptor density. Here we show that this concentration step is provided by the internalization of IL-4R subunits through a constitutive, Rac1/Pak and actin mediated endocytosis route that causes IL-4R subunits to become enriched by about two orders of magnitude within a population of cortical endosomes. Consistently, ligand induced receptor dimers are preferentially detected within these endosomes. IL-4 signalling can be blocked by pharmacological inhibitors targeting the actin polymerization machinery driving receptor internalization, placing endocytosis unambigously upstream of receptor activation. Together these observations demonstrate a role for endocytosis that is mechanistically distinct from the scaffolding function of signalling endosomes in other pathways.
Collapse
Affiliation(s)
- Kristina Kurgonaite
- Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Fetscherstr. 105, 01307 Dresden, Germany
| | - Hetvi Gandhi
- BIOTEC/Biophysics, Technische Universität Dresden, Tatzberg 47-51, 01307 Dresden, Germany
| | - Thomas Kurth
- BIOTEC/Biophysics, Technische Universität Dresden, Tatzberg 47-51, 01307 Dresden, Germany
| | - Sophie Pautot
- BIOTEC/Biophysics, Technische Universität Dresden, Tatzberg 47-51, 01307 Dresden, Germany
| | - Petra Schwille
- Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Fetscherstr. 105, 01307 Dresden, Germany
| | - Thomas Weidemann
- BIOTEC/Biophysics, Technische Universität Dresden, Tatzberg 47-51, 01307 Dresden, Germany
| | - Christian Bökel
- Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Fetscherstr. 105, 01307 Dresden, Germany
| |
Collapse
|
12
|
Gandhi H, Worch R, Kurgonaite K, Hintersteiner M, Schwille P, Bökel C, Weidemann T. Dynamics and interaction of interleukin-4 receptor subunits in living cells. Biophys J 2014; 107:2515-27. [PMID: 25468331 DOI: 10.1016/j.bpj.2014.07.077] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Revised: 07/08/2014] [Accepted: 07/24/2014] [Indexed: 11/19/2022] Open
Abstract
It has long been established that dimerization of Interleukin-4 receptor (IL-4R) subunits is a pivotal step for JAK/STAT signal transduction. However, ligand-induced complex formation at the surface of living cells has been challenging to observe. Here we report an experimental assay employing trisNTA dyes for orthogonal, external labeling of eGFP-tagged receptor constructs that allows the quantification of receptor heterodimerization by dual-color fluorescence cross-correlation spectroscopy. Fluorescence cross-correlation spectroscopy analysis at the plasma membrane shows that IL-4R subunit dimerization is indeed a strictly ligand-induced process. Under conditions of saturating cytokine occupancy, we determined intramembrane dissociation constants (K(d,2D)) of 180 and 480 receptors per μm(2) for the type-2 complexes IL-4:IL-4Rα/IL-13Rα1 and IL-13:IL-13Rα1/IL-4Rα, respectively. For the lower affinity type-1 complex IL-4:IL-4Rα/IL-2Rγ, we estimated a K(d,2D) of ∼1000 receptors per μm(2). The receptor densities required for effective dimerization thus exceed the typical, average expression levels by several orders of magnitude. In addition, we find that all three receptor subunits accumulate rapidly within a subpopulation of early sorting and recycling endosomes stably anchored just beneath the plasma membrane (cortical endosomes, CEs). The receptors, as well as labeled IL-4 and trisNTA ligands are specifically trafficked into CEs by a constitutive internalization mechanism. This may compensate for the inherent weak affinities that govern ligand-induced receptor dimerization at the plasma membrane. Consistently, activated receptors are also concentrated at the CEs. Our observations thus suggest that receptor trafficking may play an important role for the regulation of IL-4R-mediated JAK/STAT signaling.
Collapse
Affiliation(s)
- Hetvi Gandhi
- BIOTEC/Biophysics, Technische Universität Dresden, Dresden, Germany
| | - Remigiusz Worch
- BIOTEC/Biophysics, Technische Universität Dresden, Dresden, Germany; Institute of Physics, Polish Academy of Sciences, Warsaw, Poland
| | - Kristina Kurgonaite
- Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany
| | | | - Petra Schwille
- BIOTEC/Biophysics, Technische Universität Dresden, Dresden, Germany; Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Christian Bökel
- Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany
| | - Thomas Weidemann
- BIOTEC/Biophysics, Technische Universität Dresden, Dresden, Germany; Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.
| |
Collapse
|